BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21500549)

  • 1. [Expression and prognostic significance of EphA2 and EphrinA-1 in ovarian serous carcinomas].
    Han LP; Liu JF; Liu XR; Dong ZM; Suo ZH
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):179-84. PubMed ID: 21500549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas.
    Han L; Dong Z; Qiao Y; Kristensen GB; Holm R; Nesland JM; Suo Z
    Gynecol Oncol; 2005 Nov; 99(2):278-86. PubMed ID: 16061279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma.
    Xu F; Zhong W; Li J; Shanshen Z; Cui J; Nesland JM; Suo Z
    Anticancer Res; 2005; 25(4):2943-50. PubMed ID: 16080548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma.
    Wu D; Suo Z; Kristensen GB; Li S; Troen G; Holm R; Nesland JM
    Gynecol Oncol; 2004 Aug; 94(2):312-9. PubMed ID: 15297167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis.
    Holm R; Knopp S; Suo Z; Tropè C; Nesland JM
    J Clin Pathol; 2007 Oct; 60(10):1086-91. PubMed ID: 17158642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EphA2 expression is associated with aggressive features in ovarian carcinoma.
    Thaker PH; Deavers M; Celestino J; Thornton A; Fletcher MS; Landen CN; Kinch MS; Kiener PA; Sood AK
    Clin Cancer Res; 2004 Aug; 10(15):5145-50. PubMed ID: 15297418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
    Zhang MZ; Qiao YH; Suo ZH
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
    Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
    Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expressions of estrogen receptor subtypes in epithelial ovarian carcinomas].
    Han LP; Dong ZM; Qiao YH; Nesland JM; Suo ZH
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jul; 37(4):606-10. PubMed ID: 16909613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
    Wang P; Wu X; Chen W; Liu J; Wang X
    Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
    Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
    Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma.
    Wang X; Wei Z; Gao F; Zhang X; Zhou C; Zhu F; Wang Q; Gao Q; Ma C; Sun W; Kong B; Zhang L
    Anticancer Res; 2008; 28(5B):2991-6. PubMed ID: 19031945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
    Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
    Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.
    Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S
    J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.